Omniscan (Gadodiamide)

What Is Omniscan and What Is It Used For?

Omniscan (gadodiamide) is a paramagnetic contrast agent used to enhance the diagnostic quality of MRI scans. It is injected into a vein before or during the MRI examination and helps radiologists identify tumours, inflammation, vascular abnormalities, and other lesions in the brain, spine, and body.

Magnetic resonance imaging (MRI) produces detailed images of soft tissues using powerful magnetic fields and radio waves, without exposing patients to ionising radiation. In many clinical situations, however, the natural contrast between healthy and diseased tissue is insufficient to reach a confident diagnosis. Contrast agents such as Omniscan address this limitation by temporarily changing the magnetic properties of tissues where they accumulate, dramatically improving the visibility of pathological structures.

Omniscan belongs to the class of gadolinium-based contrast agents (GBCAs). Gadolinium is a rare-earth element with strong paramagnetic properties. Because free gadolinium ions are toxic, the metal is always administered bound to a chelating molecule that prevents it from interacting with the body's tissues. In Omniscan, the chelating agent is a linear, non-ionic molecule called diethylenetriaminepentaacetic acid-bismethylamide (DTPA-BMA). The resulting complex, gadodiamide, is distributed in the extracellular space after intravenous injection and is excreted unchanged through the kidneys.

Clinically, Omniscan is approved for contrast-enhanced MRI of the central nervous system (brain and spine) and for whole-body imaging, including the head and neck, thoracic cavity, liver, pancreas, kidneys, breasts, pelvis, and musculoskeletal system. It is particularly helpful for detecting and characterising brain and spinal cord tumours, demyelinating diseases such as multiple sclerosis, infections, abscesses, vascular lesions, and abnormal blood-brain barrier permeability. In body imaging, contrast enhancement supports the evaluation of focal liver and kidney lesions, breast abnormalities, and soft tissue tumours.

Omniscan is manufactured by GE Healthcare and was first approved for clinical use in the early 1990s. It is supplied as a ready-to-use solution in glass vials and prefilled syringes at a concentration of 0.5 mmol/ml (287 mg/ml). Because of its pharmacological classification, it is exclusively administered by qualified healthcare professionals in hospitals or dedicated imaging centres, never at home or by the patient.

How Does Omniscan Work?

MRI generates images based on the behaviour of hydrogen nuclei (protons) in water molecules exposed to a strong magnetic field and radiofrequency pulses. Different tissues relax at different rates after being magnetically excited, and these differences in relaxation time (known as T1 and T2) are translated into varying brightness on the final images.

Gadodiamide shortens the T1 relaxation time of nearby water protons. On T1-weighted sequences, tissues that have taken up Omniscan appear brighter than surrounding unenhanced areas. Because pathological tissues such as tumours or inflammation often have abnormal blood supply or compromised blood-brain barrier integrity, they preferentially accumulate the contrast agent and stand out clearly against normal tissue.

The r1 relaxivity of gadodiamide in plasma is approximately 4.3 L/mmol/s at 1.5 Tesla, somewhat lower than that of certain macrocyclic contrast agents. After intravenous administration at the standard dose, peak enhancement of brain lesions typically occurs within a few minutes and remains sufficient for imaging for 30 to 45 minutes. In patients with normal renal function, the elimination half-life is approximately 1.3 hours, and more than 95% of the injected dose is excreted unchanged in urine within 24 hours.

A distinguishing pharmacological feature of Omniscan is the inclusion of excess caldiamide sodium in its formulation. This additive serves as a scavenger for any gadolinium ions that may dissociate from the DTPA-BMA chelate, reducing – but not eliminating – the potential for free gadolinium to interact with biological tissues. The necessity of this additive reflects the inherently lower stability of linear non-ionic chelates compared with macrocyclic alternatives.

What Should You Know Before Receiving Omniscan?

Before receiving Omniscan, your healthcare team will assess your kidney function, allergy history, and any relevant medical conditions. Screening for renal impairment is mandatory because Omniscan is contraindicated in patients with severe kidney disease due to the risk of nephrogenic systemic fibrosis.

Contraindications

Omniscan must not be used in the following situations:

• Known hypersensitivity (allergy) to gadodiamide, to any other gadolinium-based contrast agent, or to any excipient in the formulation
• Acute kidney injury (acute renal failure)
• Severe chronic kidney disease with estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²
• Patients who have undergone or are about to undergo liver transplantation (because of the high risk of hepatorenal syndrome and NSF)
• Neonates up to 4 weeks of age (per FDA and EMA labelling)

Regulatory Status in Europe

In 2017, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that small amounts of gadolinium from linear GBCAs, including Omniscan, are retained in brain tissue. While no clinical symptoms have been definitively linked to this retention, the CHMP recommended suspending the marketing authorisation of intravenous linear GBCAs as a precautionary measure. Since then, Omniscan has not been commercially available in the European Economic Area for intravenous use. In markets where Omniscan is still available (including the United States, Canada, and parts of Asia and Latin America), regulators have issued updated safety guidance, dose minimisation recommendations, and patient information requirements.

Warnings and Precautions

Speak with your doctor or radiographer before receiving Omniscan if any of the following apply:

• You have or have had kidney disease of any severity
• You have recently undergone surgery, experienced severe infection, or have any condition that may impair kidney function
• You are over 65 years of age (kidney function often declines with age)
• You have a history of allergies, asthma, eczema, or hay fever
• You have previously reacted to any contrast agent
• You have epilepsy or a condition that lowers the seizure threshold
• You have a cardiac pacemaker, implanted defibrillator, cochlear implant, aneurysm clips, or other metal-containing implants
• You have sickle cell disease or haemolytic anaemia

Allergic and allergic-type reactions can occur with any GBCA, including Omniscan. Although severe anaphylaxis is rare, most reactions occur within the first 30 minutes after injection. For this reason, patients are kept under observation during this period, and imaging centres must have emergency equipment and trained personnel available at all times. Delayed hypersensitivity reactions may also occur up to several days after administration; any new rash, swelling, or breathing difficulty after an MRI should be reported to a doctor.

Gadodiamide has been reported to falsely lower serum calcium values on certain laboratory assays (a phenomenon known as pseudohypocalcaemia). This artefact can persist for several hours after injection. Clinicians should be aware of this and, where possible, use alternative assays (e.g. ionised calcium) if calcium measurement is required shortly after contrast administration.

Pregnancy and Breastfeeding

Omniscan should not be used during pregnancy unless clinically essential. Gadolinium-based contrast agents cross the placenta and have been detected in amniotic fluid, although the clinical consequences for the foetus are not fully understood. A large population-based cohort study published in JAMA (2016) suggested a potential association between GBCA exposure during pregnancy and a small increase in stillbirth and neonatal death rates, prompting professional societies to advise particular caution. You must inform your healthcare provider if you are pregnant or may be pregnant.

Regarding breastfeeding, current evidence indicates that only minimal amounts of GBCAs pass into breast milk, and the amount absorbed by the infant from milk is considered negligible. Many professional organisations, including the American College of Radiology and the European Society of Urogenital Radiology, state that breastfeeding can usually continue without interruption after a single standard dose of a GBCA. However, some institutions and national guidelines still recommend a 24-hour pause in breastfeeding as a conservative precaution. Discuss the best option with your radiologist and paediatrician.

Paediatric Use

Omniscan should not be administered to neonates up to 4 weeks of age. In children aged 2 years and older, Omniscan may be used at the standard dose for CNS and body imaging where non-contrast MRI is insufficient for diagnosis. In children under 2 years, the drug should only be used when absolutely necessary, after careful consideration of alternative imaging strategies and the developmental stage of the kidneys.

Elderly Patients

Patients aged 65 and older may have reduced kidney function even when serum creatinine appears normal. A laboratory measurement of estimated glomerular filtration rate is recommended before Omniscan is administered. No specific dose adjustment is required if kidney function is within an acceptable range, but repeat administrations should be spaced apart and the lowest diagnostically effective dose should always be used.

Driving and Operating Machinery

Omniscan is not expected to impair the ability to drive or operate machinery. However, some patients may experience dizziness, altered sensations, or transient vision changes shortly after injection. If this occurs, wait until symptoms have resolved before driving.

How Does Omniscan Interact with Other Drugs?

No clinically significant drug interactions with Omniscan have been identified in controlled studies. However, other medications may influence the agent's safety profile, particularly drugs that affect kidney function or modify the risk of allergic reactions. Always provide a complete medication list before the MRI.

Omniscan is not metabolised by the liver and does not engage with the cytochrome P450 system, so it does not alter blood levels of medications that depend on these enzymes. Similarly, Omniscan is not known to affect drug-transporter proteins, plasma protein binding, or other common pharmacokinetic pathways. This pharmacological inertness means the agent is unlikely to interact directly with prescription medicines, over-the-counter products, or herbal supplements.

However, indirect interactions are possible. Because Omniscan is eliminated entirely by glomerular filtration, any drug that impairs renal function can extend the agent's half-life, prolonging tissue exposure and increasing the theoretical risk of gadolinium retention or nephrogenic systemic fibrosis. Examples of nephrotoxic medications that warrant caution include non-steroidal anti-inflammatory drugs (NSAIDs), aminoglycoside antibiotics, ciclosporin, tacrolimus, amphotericin B, and certain chemotherapy agents such as cisplatin.

Patients with a low seizure threshold – for example due to epilepsy or medications like tramadol, bupropion, certain antidepressants, or antipsychotics – may be at slightly increased risk of convulsions after GBCA administration. Although such events are rare, healthcare staff should be aware of this possibility when imaging high-risk individuals.

Patients receiving beta-blockers (for example for high blood pressure, heart failure, or migraine prevention) should note that these drugs can blunt the response to adrenaline (epinephrine), which is the first-line treatment for anaphylaxis. This does not contraindicate Omniscan, but emergency protocols in imaging centres take this into account by having additional anaphylaxis treatments available.

Unlike iodinated contrast agents used in CT, Omniscan does not require withholding metformin before or after administration. Metformin can be continued as normal in patients with adequate kidney function undergoing gadolinium-enhanced MRI.

What Is the Correct Dosage of Omniscan?

The standard adult dose of Omniscan is 0.2 ml/kg body weight (equivalent to 0.1 mmol/kg) administered as a single intravenous injection. The lowest dose that provides sufficient diagnostic information should always be used. Omniscan is given exclusively by trained healthcare professionals.

Omniscan is never self-administered. A radiographer, radiologist, or MRI nurse injects it into a peripheral vein through a cannula, either manually or via a programmable power injector. The MRI scan can begin immediately after injection, with optimal lesion enhancement occurring within minutes. For patients undergoing extended imaging protocols, an additional post-contrast delay may be incorporated to capture delayed enhancement patterns.

Adults

Children (Aged 2 Years and Older)

Elderly Patients

No specific dose adjustment is required for adults over 65, but because age-related decline in glomerular filtration is common, a recent measurement of eGFR (within 3 to 6 months, or more recently if the patient has been unwell) is strongly advised. In elderly patients with borderline renal function, the lowest diagnostically adequate dose should be used, and repeat injections within short timeframes should be avoided.

Patients with Kidney Impairment

Omniscan is contraindicated in patients with severe chronic kidney disease (eGFR <30 mL/min/1.73 m²) and in patients with acute kidney injury. In patients with moderate impairment (eGFR 30–59 mL/min/1.73 m²), Omniscan should be used only when the diagnostic information is essential and not available by other means, at the lowest possible dose, and with at least 7 days between administrations. In patients already receiving haemodialysis, the procedure can be scheduled to start as soon as possible after injection, although dialysis does not prevent NSF.

Missed Dose

Because Omniscan is administered as a single injection on the day of the MRI examination, the concept of a missed dose does not apply in the usual sense. If a scheduled MRI is rescheduled, the injection is simply given on the new examination day. There is no need for the patient to take any action at home.

Overdose

Clinical overdose with Omniscan is very rare because doses are prepared and administered by trained professionals using standardised protocols. Single doses of up to 0.7 mmol/kg have been tolerated in clinical studies without significant adverse effects. In the theoretical case of overdose, treatment is supportive: monitoring of cardiovascular status, kidney function, and electrolytes, and in severe cases haemodialysis, which effectively removes gadodiamide from the bloodstream. Approximately 78% of a dose can be cleared after a single dialysis session of three hours, with further reduction after subsequent sessions.

What Are the Side Effects of Omniscan?

Most patients tolerate Omniscan well, and most side effects are mild and short-lived. The most common reactions are nausea, headache, dizziness, and transient sensations at the injection site. Serious allergic reactions and nephrogenic systemic fibrosis are rare but potentially life-threatening.

The majority of adverse reactions occur within 30 minutes of injection, which is why patients are observed during this period. Delayed reactions, appearing from several hours to days after the examination, are uncommon but recognised. Any unusual symptom appearing after an MRI with Omniscan should be reported to a doctor.

Patients with a history of allergies, asthma, or previous contrast reactions are at higher risk of hypersensitivity. Discussing this history before the examination allows the radiology team to prepare appropriately, use alternative agents where possible, or administer pre-medication to reduce the risk of reactions. It is also important to report all side effects to national pharmacovigilance agencies (such as the FDA MedWatch programme or the EMA EudraVigilance system) to help improve safety knowledge about GBCAs.

Long-term safety data on gadolinium retention continue to evolve. While there is no conclusive evidence of adverse clinical effects from gadolinium deposits in patients with normal kidney function, health authorities including the FDA and EMA recommend using the lowest diagnostically effective dose, avoiding unnecessary GBCA examinations, and, where possible, choosing macrocyclic agents, particularly for patients expected to undergo repeated examinations.

How Should Omniscan Be Stored?

Omniscan is stored under the responsibility of hospitals and imaging centres. It should be kept in its original packaging at room temperature, protected from light and freezing, and used before the printed expiry date. The solution should not be used if discoloured or if particles are visible.

Because Omniscan is exclusively administered in healthcare settings, patients do not handle or store the product themselves. Nonetheless, it is helpful to understand the conditions required for quality assurance of the medicine. Omniscan vials and prefilled syringes should be stored at room temperature (typically 20–25°C), protected from direct sunlight, and kept in their original cartons until use. Freezing should be avoided, as low temperatures may alter the physical properties of the solution.

Before administration, a healthcare professional will inspect the solution visually. Omniscan is normally clear and colourless to slightly yellow. If the liquid appears turbid, markedly discoloured, or contains visible particles, the product must not be used. The packaging should also be checked for any signs of damage; any compromised vial or syringe must be discarded according to local pharmaceutical waste regulations.

Each vial or prefilled syringe of Omniscan is intended for single-patient use. Any unused solution remaining after the examination must be discarded and must not be stored for later use. This prevents microbial contamination and ensures consistent product quality. Healthcare facilities follow strict aseptic handling procedures when preparing doses, particularly when drawing from multi-dose presentations in markets where these are available.

Disposal of unused Omniscan or empty containers should not occur through general household waste or municipal wastewater systems. Pharmaceutical waste protocols are followed to minimise environmental exposure to gadolinium, which is increasingly recognised as an emerging environmental contaminant in surface water, particularly near hospitals and imaging centres.

As with all medicines, Omniscan must be kept out of the sight and reach of children. In imaging centres, storage areas are typically secured and access is restricted to authorised personnel.

What Does Omniscan Contain?

The active substance in Omniscan is gadodiamide. Each millilitre of the solution contains 287 mg gadodiamide (equivalent to 0.5 mmol). The formulation also contains caldiamide sodium and other excipients in an aqueous solution for intravenous injection.

Omniscan is supplied as a clear, colourless to slightly yellow, ready-to-use solution for injection. The formulation is based on the gadodiamide complex, in which one gadolinium ion (Gd³⁺) is chelated by the linear non-ionic ligand diethylenetriaminepentaacetic acid-bismethylamide (DTPA-BMA). Each millilitre provides 287 mg of gadodiamide, corresponding to 0.5 mmol, or 78.6 mg of elemental gadolinium.

The inactive ingredients (excipients) of Omniscan include:

• Caldiamide sodium: A calcium-containing analogue added in slight excess to scavenge any free gadolinium ions that might dissociate from the primary chelate, thereby reducing the potential for gadolinium-calcium exchange in tissues
• Sodium hydroxide and/or hydrochloric acid: Used to adjust the pH of the solution to a physiologically acceptable range (typically 6.0 to 7.0)
• Water for injections: The solvent base that makes up the bulk of the solution

The solution is iso-osmolar with plasma at concentrations close to physiological, and it does not contain preservatives, sulphites, or antibacterial agents. Osmolality is approximately 789 mOsm/kg H&sub2;O at 37°C, and viscosity is low, which facilitates rapid bolus injection through small-bore catheters.

Omniscan is available in several pack presentations, which may vary by country and regulatory approval. Common presentations include:

• Single-dose glass vials containing 5 ml, 10 ml, 15 ml, or 20 ml of solution
• Prefilled glass syringes containing 10 ml, 15 ml, or 20 ml of solution
• Larger volume vials (40 ml and 50 ml) for use with automated power injector systems in high-volume imaging centres

Not every pack size is marketed in every country. Omniscan is manufactured by GE Healthcare. In markets where it remains authorised, it is typically available only in hospital pharmacies or dedicated imaging supply channels, not in community pharmacies. Generic or alternative brands of gadodiamide may exist in certain markets.

Frequently Asked Questions About Omniscan